Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
83
SDZXF Quote, Financials, Valuation and Earnings
Last price:
$73.00
Seasonality move
:
-5.12%
Day range:
$73.00 - $73.00
52-week range:
$36.68 - $73.45
Dividend yield:
1.02%
P/E ratio:
138.05x
P/S ratio:
3.00x
P/B ratio:
2.84x
Volume:
--
Avg. volume:
148
1-year change:
78.27%
Market cap:
$31.4B
Revenue:
$10.4B
EPS (TTM):
$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SDZXF
Sandoz Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$509K | -$0.19 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$2.6M | -$1.09 | -89.16% | -180.62% | $83.46 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.72 | 25.24% | 4402.9% | $402.18 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SDZXF
Sandoz Group AG
|
$73.00 | -- | $31.4B | 138.05x | $0.74 | 1.02% | 3.00x |
|
ACIU
AC Immune SA
|
$3.41 | $9.01 | $343M | -- | $0.00 | 0% | 66.50x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.80 | $30.00 | $9.6M | 0.77x | $0.00 | 0% | 35.68x |
|
CRSP
CRISPR Therapeutics AG
|
$53.84 | $83.46 | $5.1B | -- | $0.00 | 0% | 122.81x |
|
ONC
BeOne Medicines Ltd.
|
$337.89 | $402.18 | $37.4B | 650.16x | $0.00 | 0% | 7.55x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SDZXF
Sandoz Group AG
|
37.65% | 2.062 | -- | 0.63x |
|
ACIU
AC Immune SA
|
6.95% | 3.658 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 1.731 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.726 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.083 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SDZXF
Sandoz Group AG
|
-- | -- | 1.73% | 2.69% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Sandoz Group AG vs. Competitors
-
Which has Higher Returns SDZXF or ACIU?
AC Immune SA has a net margin of -- compared to Sandoz Group AG's net margin of -1688.87%. Sandoz Group AG's return on equity of 2.69% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SDZXFSandoz Group AG-- -- $14.1B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SDZXF or ACIU?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 164.57%. Given that AC Immune SA has higher upside potential than Sandoz Group AG, analysts believe AC Immune SA is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZXFSandoz Group AG0 0 0 ACIUAC Immune SA4 0 0 -
Is SDZXF or ACIU More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.623, suggesting its more volatile than the S&P 500 by 62.312%.
-
Which is a Better Dividend Stock SDZXF or ACIU?
Sandoz Group AG has a quarterly dividend of $0.74 per share corresponding to a yield of 1.02%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZXF or ACIU?
Sandoz Group AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Sandoz Group AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Sandoz Group AG's price-to-earnings ratio is 138.05x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 3.00x versus 66.50x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZXFSandoz Group AG3.00x 138.05x -- -- ACIUAC Immune SA66.50x -- $1.2M -$19.8M
-
Which has Higher Returns SDZXF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Sandoz Group AG's net margin of -3178.71%. Sandoz Group AG's return on equity of 2.69% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital SDZXFSandoz Group AG-- -- $14.1B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About SDZXF or ADXN?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 284.62%. Given that Addex Therapeutics Ltd. has higher upside potential than Sandoz Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZXFSandoz Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is SDZXF or ADXN More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.487, suggesting its more volatile than the S&P 500 by 48.685%.
-
Which is a Better Dividend Stock SDZXF or ADXN?
Sandoz Group AG has a quarterly dividend of $0.74 per share corresponding to a yield of 1.02%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZXF or ADXN?
Sandoz Group AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Sandoz Group AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Sandoz Group AG's price-to-earnings ratio is 138.05x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 3.00x versus 35.68x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZXFSandoz Group AG3.00x 138.05x -- -- ADXNAddex Therapeutics Ltd.35.68x 0.77x $62K -$2M
-
Which has Higher Returns SDZXF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Sandoz Group AG's net margin of -11973.12%. Sandoz Group AG's return on equity of 2.69% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital SDZXFSandoz Group AG-- -- $14.1B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About SDZXF or CRSP?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.46 which suggests that it could grow by 55.01%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZXFSandoz Group AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is SDZXF or CRSP More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.700, suggesting its more volatile than the S&P 500 by 69.984%.
-
Which is a Better Dividend Stock SDZXF or CRSP?
Sandoz Group AG has a quarterly dividend of $0.74 per share corresponding to a yield of 1.02%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZXF or CRSP?
Sandoz Group AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Sandoz Group AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Sandoz Group AG's price-to-earnings ratio is 138.05x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 3.00x versus 122.81x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZXFSandoz Group AG3.00x 138.05x -- -- CRSPCRISPR Therapeutics AG122.81x -- $889K -$106.4M
-
Which has Higher Returns SDZXF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Sandoz Group AG's net margin of 8.84%. Sandoz Group AG's return on equity of 2.69% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SDZXFSandoz Group AG-- -- $14.1B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SDZXF or ONC?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $402.18 which suggests that it could grow by 19.03%. Given that BeOne Medicines Ltd. has higher upside potential than Sandoz Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZXFSandoz Group AG0 0 0 ONCBeOne Medicines Ltd.18 0 1 -
Is SDZXF or ONC More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.26%.
-
Which is a Better Dividend Stock SDZXF or ONC?
Sandoz Group AG has a quarterly dividend of $0.74 per share corresponding to a yield of 1.02%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZXF or ONC?
Sandoz Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Sandoz Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Sandoz Group AG's price-to-earnings ratio is 138.05x while BeOne Medicines Ltd.'s PE ratio is 650.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 3.00x versus 7.55x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZXFSandoz Group AG3.00x 138.05x -- -- ONCBeOne Medicines Ltd.7.55x 650.16x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
